SPE-Driven Strategic Aggregation of Mission-Critical Service Providers in Life Sciences

DSPVG HOLDINGS sits at the intersection of purpose, science, and operating discipline. We build the infrastructure that enables life-science innovators to deliver therapies to patients safely and efficiently. We transform fragmented compliance complexity into compounding, resilient value for sponsors and investors by integrating service providers under disciplined governance, validated operating systems, and a patient-first, audit-ready culture.

Our platform unifies lower-middle-market service providers across key verticals (regulatory operations, digital quality, validation, pharmacovigilance, ESG/EHS/sustainability, and a clinical trial site network), to responsibly accelerate safe medical innovation while supporting predictable cash flows and scalable growth.

Mission

To address the limitations of compliance point solutions for life sciences sponsors by building and scaling a unified platform of mission-critical, lower-middle-market service providers.

The lived experience of our leadership drives a patient-first, audit-first culture—designing systems that reduce friction, strengthen data integrity, and help safe innovations reach the people who need them.

Vision

To be the partner of choice for life-sciences compliance and sustainability solutions worldwide—raising standards, multiplying impact, and building enduring value for all stakeholders.

Core Values

Patient-Centered Integrity

We evaluate decisions through the lens of patient outcomes and human well-being—advancing medical-innovation compliance with empathy and unwavering ethical standards.

Operational Excellence

Discipline, rigor, and continuous improvement govern our processes, enabling reliable, audit-ready execution across all portfolio companies.

Collaborative Innovation

We embrace partnerships and collective intelligence to build integrated, data-driven compliance platforms that solve complex challenges.

Transparency & Accountability

Open communication and robust governance foster trust with clients, investors, regulators, and employees.

Agility Through Structure

Our structure balances strategic flexibility with robust risk management—supporting scalable growth, flexible capital deployment, and modular exits.

Sustainable Impact

We embed ESG/EHS rigor at the core of our platform—advancing compliance while contributing to environmental and social sustainability.

What Makes Us Different

Life-sciences-native platform: Purpose-built for high-stakes, regulated workflows (GxP, ICH, MDR/IVDR)—not a generic roll-up.

Hub-and-spoke architecture with SPE protection

Each acquisition sits in a ring-fenced special purpose entity (SPE), preserving risk isolation and optionality, while the hub supplies capital, standards, and shared services.

Data and operating system advantage

SustainEnvi brings together quality, safety, ESG/EHS, and site performance into unified, audit-ready dashboards.

Commercial hardening

A portfolio-wide master services agreement (MSA), structured statements of work (SOWs), quarterly business reviews (QBRs), and bundled pricing increase share of wallet and improve retention while reducing churn.

Patient-first, audit-first discipline

Our operating culture prioritizes transparency, reliability, and outcomes—built for the realities of regulated execution.

Capital efficiency

Creative deal structures, disciplined financing, and independent-sponsor DNA support value creation through acquisition multiple arbitrage and platform-level exit optionality.

Our Company Structure

Model

Hub-and-spoke, SPE-based portfolio aggregator engineered for scale, control, and exit flexibility.

Special Purpose Entities (SPEs)

Each business operates in a dedicated legal entity to ring-fence liabilities, tailor financing, and preserve modular exit paths.

Central Shared Services

Group-level Quality & Compliance (unified eQMS, audit program, SOPs), Finance/FP&A, Business Development/CRM, Talent/L&D, and vendor management drive standardization and margin expansion.

Governance

A lean, majority-independent board with formal committees: Audit & Risk; Nomination & Governance; Compensation & Integration; and Science & Clinical.

Commercial Model

A unified MSA platform-wide, co-termed SOWs, QBR cadence, bundled pricing, and clear conflict and information-barrier procedures.

Technology Spine

SustainEnvi integrates operational KPIs (quality events, CAPA, validation, safety, carbon/Scope 1–3, and site diversity metrics) into validated, board-grade analytics, supporting transparency for investors and stakeholders.

Where We Operate

Core Portfolio Verticals

Regulatory & Safety Operations

Regulatory affairs support, inspection readiness, eCTD-related services, and pharmacovigilance operations.

Quality & Digital Infrastructure

eQMS, LIMS support, validation/CSA, and audit-trail-ready digital quality systems.

Clinical Execution & Patient Access

Clinical trial site network, decentralized/hybrid execution models, and inclusive enrollment capability.

ESG/EHS & Sustainability (SustainEnvi)

Carbon and sustainability reporting, supplier ethics, incident and EHS management, and integrated ESG/quality KPIs.

Supply & Advanced Delivery

Cold-chain logistics enablement, specialty packaging support, and controlled distribution services.

Leadership & Governance

Philip Weaver, CPA — Chairman (Non-Executive)

Former public-company CFO with deep audit and capital-markets experience. Chairs the Board and Investment Committee; senior finance and governance advisor.

Agnes Mbatu, MD, BCMAS — Co-Founder & Managing Director

Drug Safety Physician with operator experience across clinical trial sites and compliance programs. Leads operations and integration.

Richard Mbatu Ph.D — Co-Founder & Academic Partnerships

USF environmental sciences and sustainability faculty. Anchors SustainEnvi’s scientific rigor, ESG/materiality methodology, and academic partnership pipelines—supporting evidence-based frameworks and audit-ready reporting discipline. University affiliation is provided for identification purposes only and does not imply endorsement by the University of South Florida.

Cherri Miner, MD — Independent Director, Industry Advisor

Physician-executive and clinical leader providing oversight and scientific/clinical integrity support.

Greg Ball, Ph.D — Director, Safety Science

Clinical development safety and pharmacovigilance analytics leader. Strategic Partner — ASAP Process Consulting. Provides board-level advisory support on safety data analysis, monitoring strategy, and inspection readiness.

Joseph Murray — M&A Accounting Advisor

Retired KPMG M&A practice leader with 30+ years of tax experience. Supports deal structuring, tax diligence, and lender-grade reporting.

Eric Nietcho, PharmD — Director, Supply Chain, Strategic Sourcing and Global Access

Licensed pharmacist with 20 years of experience across retail, hospital, and industry pharmacy and Pharmacist-in-Charge/CEO of Global Bridge Pharmaceutical. Provides advisory support on specialty sourcing, drug-shortage solutions, controlled distribution and cold-chain readiness, and supplier qualification—linking procurement controls and supplier ethics to audit-ready Scope 3 and ESG/EHS reporting within SustainEnvi.

Emmanuel Forlack, MD, MPH — Global Health Partnerships

PAHO/WHO-experienced public-health physician focused on global partnerships and clinical trial diversity and inclusion.